# Vaccine Development * **Definition:** The process of creating and improving vaccines to prevent diseases, involving research, testing, and production to ensure their safety and efficacy. * **Taxonomy:** Healthcare Topics / Vaccine Development ## News * Selected news on the topic of **Vaccine Development**, for healthcare technology leaders * 5.1K news items are in the system for this topic * Posts have been filtered for tech and healthcare-related keywords | Date | Title | Source | | --- | --- | --- | | 5/14/2025 | [**Vaxart Publishes Positive, Complete Data from a Phase 2b Challenge Study of its First ...**](https://seekingalpha.com/pr/20104564-vaxart-publishes-positive-complete-data-from-a-phase-2b-challenge-study-of-its-first) | [[Seeking Alpha]] | | 5/7/2025 | [**RSV sent fewer babies to the hospital last winter, after new treatment and vaccine arrived**](https://www.statnews.com/2025/05/08/cdc-report-suggests-rsv-vaccine-abrysvvo-antibody-shot-beyfortus-reduced-infant-hospitalizations/) | [[STAT]] | | 4/15/2025 | [**MRNA Synthesis & Manufacturing Market Research Report 2025 and Global Forecasts to 2029**](https://finance.yahoo.com/news/mrna-synthesis-manufacturing-market-research-083500049.html) | [[Yahoo Finance]] | | 4/8/2025 | [**Are Republicans changing course on Medicare Advantage?**](https://www.statnews.com/2025/04/08/health-news-medicare-advantage-pepfar-cdc-measles-vaccine-texas-morning-rounds/?utm_campaign=rss) | [[STAT]] | | 3/27/2025 | [**Chikungunya virus virus-like particle vaccine safety and immunogenicity in adults older than 65 years**](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00372-1/abstract) | [[The Lancet]] | | 3/26/2025 | [**Feds probe disputed tip Pfizer held Covid vaccine results until after 2020 vote: WSJ**](https://www.aol.com/news/feds-probe-disputed-tip-pfizer-220652005.html) | [[AOL]] | | 3/10/2025 | [**Versatope Adds New Board Members - PR Newswire**](https://www.prnewswire.com/news-releases/versatope-adds-new-board-members-302396117.html) | [[PR Newswire]] | | 2/26/2025 | [**Global Pharmaceutical Market Size to Worth USD 2845.3 Billion by 2032, Rising Healthcare ...**](https://finance.yahoo.com/news/global-pharmaceutical-market-size-worth-143000322.html) | [[Yahoo Finance]] | | 2/26/2025 | [**Texas child is first reported US measles death in a decade as outbreak hits more than 130 people**](https://www.reuters.com/world/us/first-us-measles-death-reported-west-texas-outbreak-affects-more-than-130-people-2025-02-26/) | [[Reuters]] | | 2/18/2025 | [**GeoVax Pledges Continued Support for Vaccine Innovation, Transparency, and Public Health**](https://finance.yahoo.com/news/geovax-pledges-continued-support-vaccine-142544650.html) | [[Yahoo Finance]] | | 2/6/2025 | [**Opinion - When public health goes dark, the nation pays the price**](https://www.aol.com/opinion-public-health-goes-dark-130000989.html) | [[AOL]] | | 1/30/2025 | [**Vaccine Research Market to Grow by USD 21.4 Billion (2024-2028), High Prevalence of ...**](https://finance.yahoo.com/news/vaccine-research-market-grow-usd-051300962.html) | [[Yahoo Finance]] | | 12/12/2024 | [**Infant RSV vaccine trials on hold: FDA**](https://www.beckershospitalreview.com/pharmacy/pediatric-rsv-vaccines-on-hold-fda.html) | [[Beckers Hospital Review]] | | 12/5/2024 | [**eClinical Solutions Market to Grow by USD 12.77 Billion (2024-2028), Rising Drug Clinical ...**](https://finance.yahoo.com/news/eclinical-solutions-market-grow-usd-192000106.html) | [[Yahoo Finance]] | | 11/29/2024 | [**New 'how-to guide' for future rapid vaccine development**](https://medicalxpress.com/news/2024-11-future-rapid-vaccine.html) | [[MedicalXpress]] | | 11/22/2024 | [**Biodefense Global Market Overview 2024: Threats of Bioterrorism and Pandemics Fueling Expansion - Global Forecast to 2030 - ResearchAndMarkets.com**](http://www.businesswire.com/news/home/20241122002743/en/Biodefense-Global-Market-Overview-2024-Threats-of-Bioterrorism-and-Pandemics-Fueling-Expansion---Global-Forecast-to-2030---ResearchAndMarkets.com/?feedref=JjAwJuNHiystnCoBq_hl-RLXHJgazfQJNuOVHefdHP-D8R-QU5o2AvY8bhI9uvWSD8DYIYv4TIC1g1u0AKcacnnViVjtb72bOP4-4nHK5ieT3WxPE8m_kWI77F87CseT) | [[Business Wire]] | | 11/21/2024 | [**NINER Pharmaceutical Launches Strategic Initiative to Address IV Fluid Shortages in ... - Morningstar**](https://www.morningstar.com/news/globe-newswire/9277768/niner-pharmaceutical-launches-strategic-initiative-to-address-iv-fluid-shortages-in-the-us-and-latin-america) | [[Morningstar]] | | 11/21/2024 | [**Vicebio Advances Clinical Study of RSV/hMPV Bivalent Vaccine & Strengthens Board with ...**](https://www.prnewswire.com/news-releases/vicebio-advances-clinical-study-of-rsvhmpv-bivalent-vaccine--strengthens-board-with-appointments-of-world-class-veterans-302311876.html) | [[PR Newswire]] | | 11/19/2024 | [**Does Southeast Asia have a growing role in vaccine development? - Yahoo**](https://www.yahoo.com/finance/news/does-southeast-asia-growing-role-152950212.html) | [[Yahoo]] | | 11/19/2024 | [**Does Southeast Asia have a growing role in vaccine development?**](https://www.yahoo.com/finance/news/does-southeast-asia-growing-role-152950200.html) | [[Yahoo]] | | 11/13/2024 | [**PopVax Announces that the U.S. National Institute of Allergy and Infectious Diseases will Conduct and Sponsor the U.S.-based Phase I Clinical Trial of PopVax's Next-Generation mRNA-LNP COVID...**](http://www.businesswire.com/news/home/20241113245697/en/PopVax-Announces-that-the-U.S.-National-Institute-of-Allergy-and-Infectious-Diseases-will-Conduct-and-Sponsor-the-U.S.-based-Phase-I-Clinical-Trial-of-PopVax%E2%80%99s-Next-Generation-mRNA-LNP-COVID-19-Vaccine-as-part-of-the-U.S.-Government%E2%80%99s-Project-NextGen/?feedref=JjAwJuNHiystnCoBq_hl-RLXHJgazfQJNuOVHefdHP-D8R-QU5o2AvY8bhI9uvWSD8DYIYv4TIC1g1u0AKcacnnViVjtb72bOP4-4nHK5ieT3WxPE8m_kWI77F87CseT) | [[Business Wire]] | | 10/3/2024 | [**Enzyme-Linked Immunosorbent Assay (ELISA) Market to Grow by USD 843.9 Million (2024 ...**](https://www.prnewswire.com/news-releases/enzyme-linked-immunosorbent-assay-elisa-market-to-grow-by-usd-843-9-million-2024-2028-as-ai-drives-demand-for-frequent-diagnostic-testing-302265146.html) | [[PR Newswire]] | | 9/11/2024 | [**KEY STEPS IN THE VACCINE SCALE-UP JOURNEY - Fierce Pharma**](https://www.fiercepharma.com/premium/webinar/key-steps-vaccine-scale-journey) | [[FiercePharma]] | | 7/31/2024 | [**GeneOnline News BIO Asia-Taiwan 2024 CGT Vax Symposium**](https://www.geneonline.com/bio-asia-taiwans-cgt-vax-discovery-symposium-celltech-collaborations-innovations-and-emerging-tech-in-taiwans-vaccine-industry/) | geneonline.com | | 7/16/2024 | [**SPI Pharma, Inc. and Inimmune, Corp. Partner to Develop and Commercialize Innovative ...**](https://www.prnewswire.com/news-releases/spi-pharma-inc-and-inimmune-corp-partner-to-develop-and-commercialize-innovative-vaccine-adjuvant-systems-302198093.html) | [[PR Newswire]] | ## Topic Overview (Some LLM-derived content — please confirm with above primary sources) ### Key Players - **Evaxion Biotech**: Collaborating with MSD on preclinical vaccine candidates, leveraging AI for immunology. - **GeoVax Labs, Inc.**: A biopharmaceutical company focusing on vaccine development, including a next-generation COVID-19 vaccine. - **Soligenix, Inc.**: Developing vaccines for filoviruses and utilizing ThermoVax technology for stability. - **BioVaxys Technology Corp.**: A clinical-stage biopharmaceutical company focused on novel immunotherapies and has joined the Rapid Response Partnership Vehicle for vaccine development. - **UCLA**: University of California, Los Angeles, which is enhancing research capabilities in vaccine development. - **Novavax**: A company advancing COVID-19 and influenza vaccine development, currently in Phase 3 trials for combination vaccines. - **SPI Pharma**: A company collaborating with Inimmune to commercialize advanced adjuvant systems to enhance vaccine efficacy. - **Apriori Bio**: A biotechnology company developing an AI platform for creating vaccines resilient to rapidly-evolving viruses, receiving funding from CEPI. - **Evaxion Biotech A/S**: A biotechnology company specializing in AI-powered vaccines and immunotherapies, collaborating with MSD to advance preclinical vaccine candidates. - **PopVax**: An Indian biotechnology company selected for the U.S. Government's Project NextGen to develop a next-generation COVID-19 vaccine candidate. - **WHO**: The World Health Organization, which is prioritizing vaccine development based on socioeconomic and public health criteria. - **ATCC**: Awarded a contract by the National Cancer Institute to provide laboratory services for vaccine research. - **Longhorn Vaccines and Diagnostics**: A company developing a universal influenza vaccine and advancing diagnostic technologies for infectious diseases. - **IAVI**: An organization focused on advancing vaccine development, particularly in Africa, through innovative platforms and partnerships. - **Vaxart, Inc.**: A clinical-stage biotechnology company focused on developing oral recombinant vaccines. - **Caltech**: California Institute of Technology, involved in researching vaccine candidates. - **CureVac**: A biotechnology firm preparing to present new data on its mRNA-based cancer vaccine, showcasing advancements in oncology. - **DIOSynVax**: A clinical-stage biotechnology company developing a portfolio of vaccines, including a Bird-Flu vaccine ready for human trials. - **University of Queensland**: Establishing a facility for personalized mRNA cancer vaccines, enhancing local drug development infrastructure. ### Partnerships and Collaborations - **GeoVax Labs, Inc.**: Engaging with federal agencies to enhance U.S. biodefense capabilities through its Modified Vaccinia Ankara platform. - **BioVaxys and the Rapid Response Partnership Vehicle**: Joining forces to accelerate the development of medical countermeasures for biological threats and pandemics. - **SPI Pharma and Inimmune Corp.**: A strategic collaboration to develop advanced adjuvant systems for vaccine development, aiming to improve vaccine efficacy. - **HDT Bio and PROVIDENT consortium**: Developing strategies for rapid RNA vaccine creation against emerging infectious threats. - **IAVI and Institut Pasteur de Dakar**: Collaborating on vaccine development and manufacturing in Africa, focusing on endemic and emerging infectious diseases. - **SPI Pharma and Inimmune**: Collaborating to commercialize advanced adjuvant systems, aiming to improve vaccine efficacy and immune response. - **ATCC and National Cancer Institute**: Partnership to support research on chronic diseases and vaccine development. - **Vaxxas**: Appointed vaccine experts to enhance its product development and strategy for HD-MAP vaccine technology. - **Evaxion Biotech and MSD**: A license agreement to advance two preclinical vaccine candidates into clinical trials, enhancing their existing collaboration. - **Ragon Institute and Jameel Clinic at MIT**: Developed MUNIS, a deep learning tool to predict CD8+ T cell epitopes, enhancing vaccine development. - **Evaxion and MSD**: Option and license agreement for preclinical vaccine candidates, expanding their collaboration. - **ATCC and NIAID**: Collaborating on research to enhance understanding of tickborne diseases and contribute to vaccine development. - **Micron Biomedical and the Gates Foundation**: Collaboration to support the commercialization of needle-free vaccine technology, aimed at increasing access to vaccines in low- and middle-income countries. - **VALANX Biotech and Fina Biosolutions**: Collaborating to develop ClickCRM™, which enhances the efficacy of vaccines against bacterial infections. - **Orexo and Abera Bioscience**: Partnering to develop mucosal vaccines, starting with an intranasal influenza vaccine candidate. - **CEPI and NEC Corporation**: Collaborating to develop a vaccine against the severe fever with thrombocytopenia syndrome (SFTS) using AI technology. - **Anivive Lifesciences Inc.**: Collaborating with the Valley Fever Center for Excellence and Recipharm to advance the development of its Valley Fever vaccine. - **Korea University and Moderna**: Collaboration to develop an mRNA vaccine for hantavirus. - **University of Queensland and Vaxxas**: Collaborated to advance a patch-based mRNA vaccine for COVID-19, winning the BARDA Patch Forward Prize. - **Meiji Seika Pharma and ARCALIS**: A joint venture focused on establishing a comprehensive system for domestic mRNA vaccine production in Japan. ### Innovations, Trends, and Initiatives - **mRNA Vaccine Development**: Recent advancements in mRNA technology have led to faster and more effective vaccine development. - **mRNA Vaccine Technology**: The rapid development of mRNA vaccines during the COVID-19 pandemic has set a precedent for future vaccine development, showcasing the potential for quick responses to emerging infectious diseases. - **AI in Vaccine Development**: The use of AI platforms, such as Evaxion's and Apriori's, to analyze viral variants and design vaccines that can adapt to evolving pathogens. - **Adaptive trial designs**: Innovative approaches in vaccine trials that allow real-time modifications and improve flexibility and efficiency. - **Synthetic Biology in Vaccines**: The use of synthetic biology for precise conjugation methods in vaccine development, as seen in ClickCRM™, is a significant innovation aimed at improving vaccine efficacy. - **GeoVax's MVA Platform**: Utilizing a next-generation manufacturing platform to improve vaccine supply chain resilience and address public health needs. - **Humanized Mouse Models**: Development of humanized mouse models with a human immune system to enhance immunotherapy research and vaccine development. - **mRNA Vaccine Production**: The collaboration between EVA Pharma, DNA Script, and Quantoom Biosciences aims to streamline mRNA vaccine production processes. - **AI-Immunology Platform**: Evaxion's platform aims to enhance vaccine development through artificial intelligence. - **Novotech's Whitepaper**: Analyzes the evolving vaccine development landscape, highlighting trends in mRNA platforms and equitable vaccine access initiatives. - **mRNA Vaccines**: The rise of mRNA-based vaccines is transforming vaccine development, with companies like Moderna leading the charge. - **Men5CV Vaccine**: New meningitis vaccine developed for children, demonstrating safety and efficacy in sub-Saharan Africa. - **Needle-Free Vaccine Technology**: Micron Biomedical's innovative delivery system aims to improve vaccine accessibility and reduce the need for refrigeration, addressing barriers in immunization. - **Digital Twin Technology**: Increasing adoption in pharmaceutical manufacturing, facilitating faster and safer vaccine production. - **Machine Learning in Vaccine Research**: Utilization of machine learning to identify potential vaccine targets, such as for malaria. ### Challenges and Concerns - **Vaccine Development Complexity**: Challenges in developing vaccines for chronic infections like herpesviruses due to viral latency. - **Vaccine Efficacy and Safety**: Ongoing research is focused on improving the efficacy and safety of vaccines, particularly for older populations who may have weaker immune responses. - **Pandemic Preparedness**: The need for global preparedness against rapidly evolving viruses, as highlighted by the COVID-19 pandemic, emphasizes the importance of innovative vaccine development. - **Recruitment and trial complexity**: Ongoing challenges in recruiting participants and managing complex trial designs, particularly for therapeutic vaccines. - **Public Health Preparedness**: Need for rapid vaccine production capabilities in response to emerging infectious diseases. - **Complex Pathogens**: There is a pressing need for innovation in vaccines targeting complex pathogens like HIV and Epstein-Barr virus. - **Pre-existing Immunity**: Understanding the impact of original antigenic sin on vaccine effectiveness is crucial for developing new vaccines. - **Regulatory Hurdles**: Challenges in expediting vaccine approvals and ensuring equitable access to vaccines for vulnerable communities. - **Vaccine Skepticism**: Concerns regarding public trust in vaccines, particularly in the U.S., following political appointments and misinformation. - **Antibody-Dependent Enhancement (ADE)**: Concerns regarding dengue vaccine development and the potential for severe disease upon secondary infections. - **Malaria Vaccine Development Disruption**: Funding freeze affecting ongoing trials and research, raising safety concerns for participants. - **Supply Chain Issues**: Challenges in the traditional extraction of vaccine adjuvants, such as QS-21, due to environmental concerns and regulations. - **Supply chain vulnerabilities**: Ongoing concerns regarding the resilience of supply chains in the biopharmaceutical industry, impacting vaccine development. - **Public Trust in Vaccines**: GeoVax emphasizes the need for transparency in vaccine development to restore public trust amid concerns over vaccine safety. - **Vaccine Hesitancy**: Addressing misinformation and public skepticism remains a significant challenge for vaccine uptake. - **Antimicrobial Resistance**: Rising resistance in pathogens like Group A streptococcus and Klebsiella pneumoniae poses urgent challenges for vaccine development. - **Regulatory Compliance**: Ensuring high-quality viral vectors for gene therapies and vaccines requires adherence to Good Manufacturing Practices. - **Data Security and Compliance**: Concerns regarding data privacy and bias in AI models must be addressed to ensure equitable care in vaccine development.